Dr Reddy Q1 FY26 Earnings Results

Company Overview:

Dr. Reddy’s Laboratories Ltd is a prominent Indian pharmaceutical company offering a broad range of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations.

Financial Highlights for Q1 FY26:

• Revenue: ₹8,572 crore, up 11.38% year-on-year from ₹7,696 crore
• Total Expenses: ₹6,957 crore, up 15.81% year-on-year from ₹6,007 crore
• Consolidated Net Profit: ₹1,410 crore, up 1.29% year-on-year from ₹1,392 crore
• Earnings Per Share (EPS): ₹16.99, up 1.80% year-on-year from ₹16.69

Performance Insights:

• Revenues increased by over 11% with sustained growth across key domestic and international markets.
• Expenses rose about 16%, led by higher raw material, R&D, and operating costs, compressing margins.
• Net profit inched up by 1% as top-line growth was largely offset by cost escalation.
• The company maintains a strong presence in APIs, generics, and biosimilars, with continued investments in complex formulations.
• 

Outlook:

Dr. Reddy’s Laboratories aims to drive further growth by expanding its global footprint, developing differentiated products, and pursuing operational efficiencies in FY26 and beyond.

Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.